scholarly journals Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP‐1 and HER2 expression and converted MCF7 breast cancer subtype

2020 ◽  
Vol 177 (9) ◽  
pp. 2024-2041
Author(s):  
Noura Al‐Zeheimi ◽  
Sirin A. Adham
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Breast Cancer Subtype ◽  
Chemotherapy Resistance ◽  
Her2 Expression ◽  
Cancer Subtype

scholarly journals Performance of Mid‐Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype

2017 ◽  
Vol 22 (4) ◽  
pp. 394-401 ◽  
Author(s):  
Rosalind P. Candelaria ◽  
Roland L. Bassett ◽  
William Fraser Symmans ◽  
Maheshwari Ramineni ◽  
Stacy L. Moulder ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Breast Cancer Subtype ◽  
Breast Ultrasound ◽  
Axillary Ultrasound ◽  
Cancer Subtype ◽  
Response To Neoadjuvant Chemotherapy

Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How?

2018 ◽  
Vol 25 (12) ◽  
pp. 3535-3540 ◽  
Author(s):  
Lucy M. De La Cruz ◽  
Michael O. Harhay ◽  
Paul Zhang ◽  
Stacy Ugras
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Breast Cancer Subtype ◽  
Cancer Subtype

Molecular analysis in breast cancer subtypes and correlation with pathologic complete response (pCR) to neoadjuvant chemotherapy.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e22119-e22119
Author(s):  
Maria Gonzalez Cao ◽  
Carlota Costa ◽  
Miguel Angel Molina-Vila ◽  
Maria Teresa Cusido ◽  
Santiago Viteri Ramirez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Neoadjuvant Chemotherapy ◽  
Breast Cancer Subtype ◽  
Pathologic Complete Response ◽  
Luminal A ◽  
Luminal B ◽  
Mutational Status ◽  
Cancer Subtype ◽  
Low Levels

e22119 Background: Although it is know that pCR following neoadjuvant chemotherapy is more frequent in some subtypes of breast cancer such as Triple Negative (TN) or erb2 tumors, the predictive role of gene expression and mutation status is not well defined in this setting. Methods: We analyzed samples from 41 patients (p) prospectively treated with neoadjuvant chemotherapy (sequential AC followed by weekly TXL, or inverse sequence, plus trastuzumab for erb2 positive p). Pathologic response (PR) was classified according to Miller-Payne and RCB criteria. Radiologic evaluation was performed by ultrasonography, dynamic MR and PET-TAC after each chemotherapy sequence. We performed expression analysis of AXL, BRCA1, RAP80, BIM, EZH2, ROR1, FGFR1, PTPN12, YAP, GAS6, beta-TRCP, HIF1 alpha and ZNF217 by RT-PCR, and mutational status of p53 and PI3K genes in pretreatment biopsies. Statistical analysis was performed using Mann-Whitney U and Pearson’s chi-squared tests. Results: pCR was detected in 5 p (3TN, 2 erb2) of 25 p (9 luminal A, 5 luminal B, 6 erb2 and 5 TN) evaluated for PR at time of submitting this abstract. TN tumors had lower levels of RAP80 (p=.0013), PTPN12 (p=.003), beta TRCP (p=.001), ZNF217 (p=.014) and YAP (p=.097). Luminal B tumors had low levels of YAP and the highest levels of FGFR1 (p=.09) and ZNF217 (p=.014). Luminal A tumors had high levels of beta-TRCP (p=.003). We found no differences in BRCA1, AXL, BIM, EZH2, ROR1, GAS6 and HIF1 levels by breast cancer subtype. P with low levels of FGFR1 (p=.087), HIF1alpha (p=.07) or EZH2 (p=.005) had higher probability of pCR. No pCR was observed in p with higher levels of AXL, EZH2, RAP80, GAS6, beta TRCP, HIF alpha. Four p had p53 mutations (1 luminal B, 1 erb2 and 2 TN) and 4 p had PI3K mutations (2 luminal A, 1 erb2, 1 luminal B). There was no correlation between p53 status and PR. P with PI3K mutations did not achieve pCR vs 46% of p with wild type PI3K (p=.23). Conclusions: Gene expression profile varies by breast cancer subtype. Chemosensitivity could be higher in tumors with lower levels of FGFR1, HIF1alpha or EZH2. Further results will be presented.

The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype

2018 ◽  
Vol 18 (2) ◽  
pp. e219-e229 ◽  
Author(s):  
Naoki Hayashi ◽  
Yuko Takahashi ◽  
Naoko Matsuda ◽  
Hiroko Tsunoda ◽  
Atsushi Yoshida ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Primary Breast Cancer ◽  
Breast Cancer Subtype ◽  
Tumor Stage ◽  
Nodal Status ◽  
Prognostic Effect ◽  
Cancer Subtype

Precise discrimination of Luminal A breast cancer subtype using an aptamer in vitro and in vivo

Nanoscale ◽  
2020 ◽  
Vol 12 (38) ◽  
pp. 19689-19701 ◽  
Author(s):  
Mei Liu ◽  
Biao Zhang ◽  
Zhiyang Li ◽  
Zhifei Wang ◽  
Song Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Subtype ◽  
Dna Aptamer ◽  
Luminal A ◽  
Cancer Subtype

A truncated DNA aptamer for precise discrimination of Luminal A breast cancer subtype was developed.

Sign in / Sign up

Export Citation Format

Share Document